FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2152063648> ?p ?o ?g. }

• W2152063648 endingPage "875" @default.
• W2152063648 startingPage "875" @default.
• W2152063648 abstract "Combination therapy with alendronate and estrogen for 2 years increases bone mineral density at the spine and hip more than does therapy with either agent alone. Changes in bone mineral density after discontinuation of therapy have not been compared directly.To determine the rate of bone loss when therapy with alendronate, estrogen, or both agents is discontinued.Double-blind, placebo-controlled discontinuation trial.18 U.S. centers.244 postmenopausal, hysterectomized women 44 to 77 years of age.2 years of therapy with alendronate, 10 mg/d (n = 92); conjugated estrogen, 0.625 mg/d (n = 143); alendronate and conjugated estrogen (n = 140); or placebo (n = 50). At year 3, women were allocated into five groups: Twenty-eight women continued to take placebo and 44 women continued to take combination therapy, but 50 women taking alendronate, 81 taking conjugated estrogen, and 41 taking combination therapy were switched to placebo.Bone mineral density and biochemical markers of bone turnover.Women taking alendronate or combination therapy who were switched to placebo for year 3 of the study maintained bone mass. Bone mineral density in these women was 4.1% (CI, 2.6% to 5.7%) and 6.6% (CI, 5.0% to 8.2%) higher, respectively, at the spine (P < 0.001 for both treatment comparisons) and 3.5% (CI, 2.3% to 4.6%) and 3.0% (CI, 1.8% to 4.2%) higher, respectively, at the trochanter (P < 0.001 for both treatment comparisons) than that in women previously taking estrogen who were switched to placebo. In contrast, women who were taking estrogen and were switched to placebo during year 3 experienced a 4.5% decrease at the spine (95% CI, -5.0% to -4.0%) and a 2.4% decrease at the trochanter (CI, -2.7% to -2.1%) (P < 0.001 for both changes). Compared with women who took placebo for 3 years, women who took estrogen for 2 years and were then switched to placebo had a bone mineral density that was 2.9% higher (CI, 1.2% to 4.6%) at the spine (P < 0.05) and 2.9% higher (CI, 1.6% to 4.2%) at the trochanter (P < 0.001). Changes in biochemical markers during year 3 did not differ among the groups that discontinued active treatment.Accelerated bone loss is seen after withdrawal of estrogen therapy but not after withdrawal of alendronate or combination therapy. The differential effects after withdrawal of therapy should be considered in the management of postmenopausal osteoporosis." @default.
• W2152063648 created "2016-06-24" @default.
• W2152063648 creator A5002462495 @default.
• W2152063648 creator A5009609882 @default.
• W2152063648 creator A5010429279 @default.
• W2152063648 creator A5016432042 @default.
• W2152063648 creator A5025108169 @default.
• W2152063648 creator A5026891957 @default.
• W2152063648 creator A5032976877 @default.
• W2152063648 creator A5040802687 @default.
• W2152063648 creator A5045290077 @default.
• W2152063648 creator A5048031613 @default.
• W2152063648 creator A5055380940 @default.
• W2152063648 creator A5055923554 @default.
• W2152063648 creator A5060835624 @default.
• W2152063648 creator A5061030125 @default.
• W2152063648 creator A5080111635 @default.
• W2152063648 date "2002-12-03" @default.
• W2152063648 modified "2023-10-11" @default.
• W2152063648 title "Significant Differential Effects of Alendronate, Estrogen, or Combination Therapy on the Rate of Bone Loss after Discontinuation of Treatment of Postmenopausal Osteoporosis" @default.
• W2152063648 cites W1975849827 @default.
• W2152063648 cites W2004236425 @default.
• W2152063648 cites W2013449928 @default.
• W2152063648 cites W2023471859 @default.
• W2152063648 cites W2024975817 @default.
• W2152063648 cites W2035593552 @default.
• W2152063648 cites W2037023285 @default.
• W2152063648 cites W2043759393 @default.
• W2152063648 cites W2074556387 @default.
• W2152063648 cites W2097506722 @default.
• W2152063648 cites W2104949625 @default.
• W2152063648 cites W2112629831 @default.
• W2152063648 cites W2124527463 @default.
• W2152063648 cites W2151649765 @default.
• W2152063648 cites W2153009489 @default.
• W2152063648 cites W2162255898 @default.
• W2152063648 cites W2340559658 @default.
• W2152063648 cites W2734840715 @default.
• W2152063648 cites W3146425672 @default.
• W2152063648 cites W2341127235 @default.
• W2152063648 doi "https://doi.org/10.7326/0003-4819-137-11-200212030-00008" @default.
• W2152063648 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12458987" @default.
• W2152063648 hasPublicationYear "2002" @default.
• W2152063648 type Work @default.
• W2152063648 sameAs 2152063648 @default.
• W2152063648 citedByCount "205" @default.
• W2152063648 countsByYear W21520636482012 @default.
• W2152063648 countsByYear W21520636482013 @default.
• W2152063648 countsByYear W21520636482014 @default.
• W2152063648 countsByYear W21520636482015 @default.
• W2152063648 countsByYear W21520636482016 @default.
• W2152063648 countsByYear W21520636482017 @default.
• W2152063648 countsByYear W21520636482018 @default.
• W2152063648 countsByYear W21520636482019 @default.
• W2152063648 countsByYear W21520636482020 @default.
• W2152063648 countsByYear W21520636482021 @default.
• W2152063648 countsByYear W21520636482022 @default.
• W2152063648 crossrefType "journal-article" @default.
• W2152063648 hasAuthorship W2152063648A5002462495 @default.
• W2152063648 hasAuthorship W2152063648A5009609882 @default.
• W2152063648 hasAuthorship W2152063648A5010429279 @default.
• W2152063648 hasAuthorship W2152063648A5016432042 @default.
• W2152063648 hasAuthorship W2152063648A5025108169 @default.
• W2152063648 hasAuthorship W2152063648A5026891957 @default.
• W2152063648 hasAuthorship W2152063648A5032976877 @default.
• W2152063648 hasAuthorship W2152063648A5040802687 @default.
• W2152063648 hasAuthorship W2152063648A5045290077 @default.
• W2152063648 hasAuthorship W2152063648A5048031613 @default.
• W2152063648 hasAuthorship W2152063648A5055380940 @default.
• W2152063648 hasAuthorship W2152063648A5055923554 @default.
• W2152063648 hasAuthorship W2152063648A5060835624 @default.
• W2152063648 hasAuthorship W2152063648A5061030125 @default.
• W2152063648 hasAuthorship W2152063648A5080111635 @default.
• W2152063648 hasConcept C126322002 @default.
• W2152063648 hasConcept C126894567 @default.
• W2152063648 hasConcept C141071460 @default.
• W2152063648 hasConcept C142724271 @default.
• W2152063648 hasConcept C170033053 @default.
• W2152063648 hasConcept C204787440 @default.
• W2152063648 hasConcept C27081682 @default.
• W2152063648 hasConcept C2776541429 @default.
• W2152063648 hasConcept C2776886416 @default.
• W2152063648 hasConcept C2776999253 @default.
• W2152063648 hasConcept C2777164284 @default.
• W2152063648 hasConcept C2778715236 @default.
• W2152063648 hasConcept C2779329777 @default.
• W2152063648 hasConcept C2779809032 @default.
• W2152063648 hasConcept C71924100 @default.
• W2152063648 hasConceptScore W2152063648C126322002 @default.
• W2152063648 hasConceptScore W2152063648C126894567 @default.
• W2152063648 hasConceptScore W2152063648C141071460 @default.
• W2152063648 hasConceptScore W2152063648C142724271 @default.
• W2152063648 hasConceptScore W2152063648C170033053 @default.
• W2152063648 hasConceptScore W2152063648C204787440 @default.
• W2152063648 hasConceptScore W2152063648C27081682 @default.
• W2152063648 hasConceptScore W2152063648C2776541429 @default.
• W2152063648 hasConceptScore W2152063648C2776886416 @default.
• W2152063648 hasConceptScore W2152063648C2776999253 @default.

• next